Investigational Drug Details
| Drug ID: | D224 |
| Drug Name: | Mefenamic acid |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00784 |
| DrugBank Description: | A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. |
| PubChem ID: | 4044 |
| CasNo: | 61-68-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1 |
| Structure: |
|
| InChiKey: | HYYBABOKPJLUIN-UHFFFAOYSA-N |
| Molecular Weight: | 241.2851 |
| DrugBank Targets: | Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1 |
| DrugBank MoA: | Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced. |
| DrugBank Pharmacology: | Mefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase. |
| DrugBank Indication: | For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|